|
KMID : 1145520160020020073
|
|
Journal of Radiopharmaceuticals and Molecular Probes
2016 Volume.2 No. 2 p.73 ~ p.83
|
|
|
[18F]Labeled 2-nitroimidazole derivatives for hypoxia imaging
|
|
Seelam Sudhakara Reddy
Lee Yun-Sang
Jeong Jae-Min
|
|
|
Abstract
|
|
|
|
Imaging hypoxia using positron emission tomography (PET) is of great importance for cancer therapy. [18F] Fluoromisonidazole (FMISO) was the first PET agent used for imaging tumor hypoxia. Various radiolabeled nitroimidazole derivatives such as [18F]fluoroerythronitroimidazole (FETNIM), [18F]1-α-D-(2-deoxy-2-fluoroarabinofuranosyl)-2- nitroimidazole(FAZA), 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]-trifluoropropyl)acetamide ([18F]EF-3), [18F]2-(2-nitro-1Himidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide (EF-5), 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)- 1H-1,2,3,-triazol-1-yl)-propan-1-ol ([18F]HX-4), and [18F]fluoroetanidazole (FETA) were developed successively. However, these imaging agents still produce PET images with limited resolution; the lower blood flow in hypoxic tumors compared to normoxic tumors results in low uptake of the agents in hypoxic tumors. Thus, the development of better imaging agents is necessary.
|
|
|
KEYWORD
|
|
|
[18F]FMISO, 2-nitroimidazole, PET, fluorine-18, hypoxia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|